National class action approved for users of this antipsychotic drug – GLOBAL

March 14, 2024

The companies behind a prescription drug that was recently approved to treat symptoms of agitation in Alzheimer’s patients are facing a class-action lawsuit over alleged “harmful side effects” to patients.

The lawsuit relates to the antipsychotic drug Rexulti, which was approved by Health Canada in January for managing agitation associated with dementia due to Alzheimer’s disease in patients with aggressive behaviour that is unresponsive to non-pharmacological approaches.

Rexulti was also previously approved in Canada for the treatment of schizophrenia in adults and as an additional therapy to antidepressants in adults with major depressive disorder (MDD).

The Superior Court of Quebec authorized a national class action earlier this month on behalf of all Canadians who were prescribed and used Rexulti and developed some side effects.

Read more: https://globalnews.ca/news/10359080/antipsychotic-drug-class-action-canada/